Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.54 in the latest trading session, marking a +0.85% move from the prior day.
Novartis Terminates Sale of Sandoz Dermatology Business
by Zacks Equity Research
Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
Amarin's Stock Plunges Following Unfavorable Patent Ruling
by Zacks Equity Research
Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.
COVID-19 Claiming Lives But Therapeutics Could Be on the Way
by Sejuti Banerjea
The WHO's Solidarity testing project could be good news for the world.
Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma
by Zacks Equity Research
Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.90, moving +0.77% from the previous trading session.
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
Novartis to Donate Generic Hydroxychloroquine for Coronavirus
by Zacks Equity Research
Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $7.26, marking a +1.26% move from the previous day.
Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus
by Ekta Bagri
Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.
J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
by Zacks Equity Research
Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.
Mallinckrodt Up on New York's Support for Opioid Settlement
by Zacks Equity Research
Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
by Zacks Equity Research
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4
by Zacks Equity Research
Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.
Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat
by Zacks Equity Research
Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.
Mallinckrodt Gains on Opioid Settlement, Beats on Q4 Earnings
by Zacks Equity Research
Mallinckrodt (MNK) signs a $1.6-billion agreement for its ongoing opioid litigation and reports better-than-expected Q4 results.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
3 Best Drugmakers That Are Immune to Coronavirus Fright
by Manaswita Ghosh Dutta
The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.
Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize
by Zacks Equity Research
Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.
Teva (TEVA) Q4 Earnings In Line, Sales Beat, Stock Up
by Zacks Equity Research
Teva Pharmaceutical (TEVA) matches earnings estimates but beats the same for sales. Shares rise in pre-market trading.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $12.10, moving +0.33% from the previous trading session.
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
by Zacks Equity Research
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.